## Georgia Xiromerisiou

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1034896/publications.pdf

Version: 2024-02-01

79 papers

4,594 citations

28 h-index 64 g-index

80 all docs 80 docs citations

80 times ranked

8894 citing authors

#	Article	IF	CITATIONS
1	Plasma Glutathione and Prodromal Parkinson's Disease Probability. Movement Disorders, 2022, 37, 200-205.	2.2	10
2	CADASIL in Greece: Mutational spectrum and clinical characteristics based on a systematic review and pooled analysis of published cases. European Journal of Neurology, 2022, 29, 810-819.	1.7	6
3	Dietary Inflammatory Index score and prodromal Parkinson's disease incidence: The HELIAD study. Journal of Nutritional Biochemistry, 2022, 105, 108994.	1.9	6
4	A novel task-specific dystonia type: Hemifacial spasm in a photographer. Neurological Sciences, 2021, 42, 1151-1152.	0.9	1
5	Frailty and Prodromal Parkinson's Disease: Results From the HELIAD Study. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 622-629.	1.7	16
6	Identification of a novel de novo KMT2B variant in a Greek dystonia patient via exome sequencing genotype–phenotype correlations of all published cases. Molecular Biology Reports, 2021, 48, 371-379.	1.0	3
7	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	9.4	198
8	Factors associated with recurrent transient global amnesia: systematic review and pathophysiological insights. Reviews in the Neurosciences, 2021, 32, 751-765.	1.4	11
9	Fahr's syndrome due to hypoparathyroidism revisited: A case of parkinsonism and a review of all published cases. Clinical Neurology and Neurosurgery, 2021, 202, 106514.	0.6	9
10	Late life psychotic features in prodromal Parkinson's disease. Parkinsonism and Related Disorders, 2021, 86, 67-73.	1.1	5
11	Intergenic SNPs in Obstructive Sleep Apnea Syndrome: Revealing Metabolic, Oxidative Stress and Immune-Related Pathways. Diagnostics, 2021, 11, 1753.	1.3	1
12	α‧ynuclein ( <scp><i>SNCA</i></scp> ) <scp>A30G</scp> Mutation as a Cause of a Complex Phenotype Without Parkinsonism. Movement Disorders, 2021, 36, 2209-2212.	2.2	1
13	$\langle i \rangle$ SORL1 $\langle i \rangle$ mutation in a Greek family with Parkinson's disease and dementia. Annals of Clinical and Translational Neurology, 2021, 8, 1961-1969.	1.7	7
14	Clinically Silent Small Vessel Disease of the Brain in Patients with Obstructive Sleep Apnea Hypopnea Syndrome. Diagnostics, 2021, 11, 1673.	1.3	3
15	Sleep disordered breathing from preschool to early adult age and its neurocognitive complications: A preliminary report. Sleep Science, 2021, 14, 140-149.	0.4	6
16	Hereditary cerebral amyloid angiopathy mimicking CADASIL syndrome. European Journal of Neurology, 2021, 28, 3866-3869.	1.7	4
17	Association of the Polygenic Risk Score With the Probability of Prodromal Parkinson's Disease in Older Adults. Frontiers in Molecular Neuroscience, 2021, 14, 739571.	1.4	6
18	A novel homozygous SACS mutation identified by whole exome sequencing-genotype phenotype correlations of all published cases. Journal of Molecular Neuroscience, 2020, 70, 131-141.	1.1	19

#	Article	IF	Citations
19	Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. Brain, 2020, 143, 2929-2944.	3.7	29
20	Neurodegeneration and Inflammation—An Interesting Interplay in Parkinson's Disease. International Journal of Molecular Sciences, 2020, 21, 8421.	1.8	160
21	Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy revisited. Neurology: Genetics, 2020, 6, e434.	0.9	22
22	A Prospective Validation of the Updated Movement Disorders Society Research Criteria for Prodromal Parkinson's Disease. Movement Disorders, 2020, 35, 1802-1809.	2.2	15
23	Posterior reversible encephalopathy in a GT1a positive oculopharyngeal variant of Guillain-Barré syndrome: A case-report and review of the literature. Clinical Neurology and Neurosurgery, 2020, 196, 106037.	0.6	4
24	Assessment of the reporting quality of double-blind RCTs for ischemic stroke based on the CONSORT statement. Journal of the Neurological Sciences, 2020, 415, 116938.	0.3	15
25	Association between <i>Helicobacter py</i> lori infection and Guillainâ€Barré Syndrome: A metaâ€analysis. European Journal of Clinical Investigation, 2020, 50, e13218.	1.7	21
26	Prevalence of <i>C9orf72</i> hexanucleotide repeat expansion in Greek patients with sporadic ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 2020, 21, 470-472.	1.1	3
27	Advancements in the Treatment of Cerebrovascular Complications of Cancer. Current Treatment Options in Neurology, 2020, 22, 1.	0.7	3
28	Organochlorine pesticide levels in Greek patients with Parkinson's disease. Toxicology Reports, 2020, 7, 596-601.	1.6	27
29	Screening for the C9ORF72 Expansion in Greek Huntington Disease Phenocopies and Controls and Meta-analysis of Current Data. Tremor and Other Hyperkinetic Movements, 2020, 10, 5.	1.1	5
30	Motor function and the probability of prodromal Parkinson's disease in older adults. Movement Disorders, 2019, 34, 1345-1353.	2.2	16
31	<i>PDXK</i> mutations cause polyneuropathy responsive to pyridoxal 5′â€phosphate supplementation. Annals of Neurology, 2019, 86, 225-240.	2.8	54
32	The role of C9orf72 in neurodegenerative disorders: a systematic review, an updated meta-analysis, and the creation of an online database. Neurobiology of Aging, 2019, 84, 238.e25-238.e34.	1.5	27
33	Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology, 2019, 92, e2261-e2272.	1.5	34
34	New molecular diagnostic trends and biomarkers for amyotrophic lateral sclerosis. Human Mutation, 2019, 40, 361-373.	1.1	15
35	Mediterranean diet adherence is related to reduced probability of prodromal Parkinson's disease. Movement Disorders, 2019, 34, 48-57.	2.2	134
36	Genetic variations in the SULF1 gene alter the risk of cervical cancer and precancerous lesions. Oncology Letters, 2018, 16, 3833-3841.	0.8	9

#	Article	IF	CITATIONS
37	Impact of reactive oxygen species generation on <i>Helicobacter pylori</i> -related extragastric diseases: a hypothesis. Free Radical Research, 2017, 51, 73-79.	1.5	26
38	A novel mutation in TREM2 gene causing Nasu-Hakola disease and review of the literature. Neurobiology of Aging, 2017, 53, 194.e13-194.e22.	1.5	61
39	<i>Helicobacter pylori</i> i>on portal hypertension-related hepatic encephalopathy.  Immunopharmacology and Immunotoxicology, 2017, 39, 105-106.	1.1	1
40	Periodic Paralysis and Encephalopathy as Initial Manifestations of Graves' Disease. Neurologist, 2017, 22, 134-137.	0.4	3
41	Evaluation of the interaction between LRRK2 and PARK16 loci in determining risk of Parkinson's disease: analysis of a large multicenter study. Neurobiology of Aging, 2017, 49, 217.e1-217.e4.	1.5	7
42	Genotype-phenotype correlations and expansion of the molecular spectrum of AP4M1-related hereditary spastic paraplegia. Orphanet Journal of Rare Diseases, 2017, 12, 172.	1.2	17
43	Genomic variants in the FTO gene are associated with sporadic amyotrophic lateral sclerosis in Greek patients. Human Genomics, $2017,11,30.$	1.4	21
44	Genetic and phenotypic characterization of complex hereditary spastic paraplegia. Brain, 2016, 139, 1904-1918.	3.7	170
45	Large-scale assessment of polyglutamine repeat expansions in Parkinson disease. Neurology, 2015, 85, 1283-1292.	1.5	25
46	The clinical and genetic heterogeneity of paroxysmal dyskinesias. Brain, 2015, 138, 3567-3580.	3.7	129
47	Novel single base-pair deletion in exon 1 of XK gene leading to McLeod syndrome with chorea, muscle wasting, peripheral neuropathy, acanthocytosis and haemolysis. Journal of the Neurological Sciences, 2014, 339, 220-222.	0.3	4
48	The protective effect of LRRK2 p.R1398H on risk of Parkinson's disease is independent of MAPT and SNCA variants. Neurobiology of Aging, 2014, 35, 266.e5-266.e14.	1.5	36
49	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	9.4	1,685
50	Assessment of Parkinson's disease risk loci in Greece. Neurobiology of Aging, 2014, 35, 442.e9-442.e16.	1.5	18
51	THAP1 mutations in a Greek primary blepharospasm series. Parkinsonism and Related Disorders, 2013, 19, 404-405.	1.1	14
52	TDP-43 pathology in a patient carrying G2019S LRRK2Âmutation and a novel p.Q124E MAPT. Neurobiology of Aging, 2013, 34, 2889.e5-2889.e9.	1.5	41
53	The interplay between environmental and genetic factors in Parkinson's disease susceptibility: The evidence for pesticides. Toxicology, 2013, 307, 17-23.	2.0	95
54	The syndrome of deafnessâ€dystonia: Clinical and genetic heterogeneity. Movement Disorders, 2013, 28, 795-803.	2.2	25

#	Article	IF	Citations
55	Familial case of speechâ€induced tongueâ€protrusion dystonia. Movement Disorders, 2013, 28, 1315-1315.	2.2	3
56	A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants. Journal of Medical Genetics, 2012, 49, 721-726.	1.5	94
57	The MAPT p.A152T variant is a risk factor associated with tauopathies with atypical clinical and neuropathological features. Neurobiology of Aging, 2012, 33, 2231.e7-2231.e14.	1.5	60
58	Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology, 2012, 79, 659-667.	1.5	119
59	THAP1 mutations and dystonia phenotypes: Genotype phenotype correlations. Movement Disorders, 2012, 27, 1290-1294.	2.2	126
60	Identical twins with Leucine rich repeat kinase type 2 mutations discordant for Parkinson's disease. Movement Disorders, 2012, 27, 1323-1323.	2.2	19
61	Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease. Movement Disorders, 2012, 27, 400-405.	2.2	56
62	$\hat{l}^2$ -Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Molecular Genetics and Metabolism, 2011, 104, 149-152.	0.5	47
63	A large-scale genetic association study to evaluate the contribution of Omi/HtrA2 (PARK13) to Parkinson's disease. Neurobiology of Aging, 2011, 32, 548.e9-548.e18.	1.5	56
64	Angiotensin-converting enzyme tag single nucleotide polymorphisms in patients with intracerebral hemorrhage. Pharmacogenetics and Genomics, 2011, 21, 136-141.	0.7	14
65	Lack of association of the <i>UCHL‶</i> gene with Parkinson's disease in a greek cohort: A haplotypeâ€ŧagging approach. Movement Disorders, 2011, 26, 1955-1957.	2.2	2
66	Independent and joint effects of the <i>MAPT</i> and <i>SNCA</i> genes in Parkinson disease. Annals of Neurology, 2011, 69, 778-792.	2.8	92
67	Interleukin-1B and interleukin-1 receptor antagonist gene polymorphisms in Greek multiple sclerosis (MS) patients with bout-onset MS. Neurological Sciences, 2010, 31, 253-257.	0.9	19
68	Gain-of-function variant in GLUD2 glutamate dehydrogenase modifies Parkinson's disease onset. European Journal of Human Genetics, 2010, 18, 336-341.	1.4	44
69	Genetic association studies in patients with traumatic brain injury. Neurosurgical Focus, 2010, 28, E9.	1.0	106
70	Genetic basis of Parkinson disease. Neurosurgical Focus, 2010, 28, E7.	1.0	35
71	Acute bilateral thalamic infarction as a cause of acute dementia and hypophonia after occlusion of the artery of Percheron. Journal of the Neurological Sciences, 2009, 283, 175-177.	0.3	19
72	Genetic Susceptibility to Primary Intracerebral Haemorrhage. European Neurological Review, 2009, 4, 44.	0.5	2

#	ARTICLE	IF	CITATION
73	Association between AKT1 gene and Parkinson's disease: A protective haplotype. Neuroscience Letters, 2008, 436, 232-234.	1.0	58
74	Neither Replication nor Simulation Supports a Role for the Axon Guidance Pathway in the Genetics of Parkinson's Disease. PLoS ONE, 2008, 3, e2707.	1.1	17
75	The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations. Neuroscience Letters, 2006, 395, 227-229.	1.0	14
76	Autoantibodies to alpha-synuclein in inherited Parkinson's disease. Journal of Neurochemistry, 2006, 101, 749-756.	2.1	161
77	Association of $\hat{l}$ ±-synuclein Rep1 polymorphism and Parkinson's disease: Influence of Rep1 on age at onset. Movement Disorders, 2006, 21, 534-539.	2.2	49
78	How genetics research in Parkinson's disease is enhancing understanding of the common idiopathic forms of the disease. Current Opinion in Neurology, 2005, 18, 706-711.	1.8	62
79	Lack of evidence for a genetic association between FGF20 and Parkinson's disease in Finnish and Greek patients. BMC Neurology, 2005, $5,11.$	0.8	37